文献速递造血干细胞移植与细胞治疗

小分子BCL6抑制剂有效治疗非硬皮病样慢性移植物抗宿主病小鼠

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.
PubMed 文献 · Blood · 2018-10-02

本研究探讨BCL6在慢性移植物抗宿主病(cGVHD)中的作用,发现供者T细胞和B细胞表达BCL6是cGVHD发生所必需,小分子BCL6抑制剂可逆转伴生发中心反应的多器官损伤及闭塞性细支气管炎小鼠模型的活动性cGVHD,但对以硬皮病为主要表现的小鼠无效。

要点

  • 供者T细胞和B细胞表达BCL6是cGVHD发生所必需,BCL6为治疗靶点。
  • 小分子BCL6抑制剂可逆转伴生发中心反应的多器官损伤及闭塞性细支气管炎小鼠的活动性cGVHD。
  • 该抑制剂对以硬皮病为主要表现的cGVHD小鼠无效。

核心结论

  • BCL6是cGVHD发生所必需,小分子BCL6抑制剂可逆转伴生发中心反应的非硬皮病样cGVHD小鼠模型的活动性疾病,提示靶向BCL6可能为抗体驱动的cGVHD患者提供新的治疗途径。

研究设计与样本

  • 研究采用cGVHD小鼠模型,包括多器官系统损伤伴闭塞性细支气管炎及强烈生发中心反应的模型,以及以硬皮病为主要表现的cGVHD模型,评估小分子BCL6抑制剂的治疗作用。

主要发现

  • 供者T细胞和B细胞表达BCL6是cGVHD发生所必需,提示BCL6为治疗靶点。
  • 小分子BCL6抑制剂逆转了伴生发中心反应的多器官系统损伤及闭塞性细支气管炎小鼠模型的活动性cGVHD。
  • 小分子BCL6抑制剂未逆转以硬皮病为主要表现的cGVHD小鼠的疾病。

临床怎么用

  • 对于抗体驱动的cGVHD患者,靶向BCL6代表一种对生发中心主调控因子具有特异性的新方法,可扩展目前可用的二线药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patient outcomes for steroid-dependent or -refractory chronic graft-versus-host diesease (cGVHD) are poor, and only ibrutinib has been US Food and Drug Administration (FDA) approved for this indication. cGVHD is often driven by the germinal center (GC) reaction, in which T follicular helper cells interact with GC B cells to produce antibodies that are associated with disease pathogenesis. The transcriptional corepressor B-cell lymphoma 6 (BCL6) is a member of the Broad-complex, Tramtrack, and Bric-abrac/poxvirus and zinc finger (BTB/POZ) transcription factor family and master regulator of the immune cells in the GC reaction. We demonstrate that BCL6 expression in both donor T cells and B cells is necessary for cGVHD development, pointing to BCL6 as a therapeutic cGVHD target. A small-molecule BCL6 inhibitor reversed active cGVHD in a mouse model of multiorgan system injury with bronchiolitis obliterans associated with a robust GC reaction, but not in cGVHD mice with scleroderma as the prominent manifestation. For cGVHD patients with antibody-driven cGVHD, targeting of BCL6 represents a new approach with specificity for a master GC regulator that would extend the currently available second-line agents.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Paz K, Flynn R, Du J, et al. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2018. PMID: 30279226. doi:10.1182/blood-2018-03-839993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。